drugset / Trial / NCT00564031

Hormonal Replacement Therapy and Small Artery Function

NCT00564031

Phase 3 Completed 66 enrolled Karolinska University Hospital
RandomizedParallel-groupDouble-blindPrevention

Summary

Endothelial dysfunction in resistance arteries in women after the menopause is important for the development of high blood pressure and cardiovascular disease

Timeline

Start
2003-01
Primary completion
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Femanest Unknown 2 mg
Subject medroxyprogesterone acetate Other / unclassified 5 mg

Indications

No indication recorded.